The frequency of NPM1 mutation reported in AML is highly variable in the literature, ranging from 4% to 100%, presumably attributable, at least in part, to case selection [5], [15], [16], [18], [19], [20]. This evidence concerns the gene NPM1 and acute myeloid leukemia.